Home > Analytics > BIOCON

BIOCON
Intrinsic Value | Fundamental Analysis

BOM : 532523     NSE : BIOCON    
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Good [Stock is Cheap]
Debt : High
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward
Pledged Shares : None or < 25%
Apr 26,2024
Price(EOD): ₹ 307.00
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Pharmaceuticals & Drugs
MCap: ₹ 36,858.42 Cr
Value of ₹ 1 Lac invested in BIOCON
on Apr 30,2019 (price: ₹ 296.45)

₹ 1 L

₹ 1.04 L

1W : 13.3% 1M : 21.8% 1Y : 29.3%
COMMUNITY POLL
for BIOCON
Please provide your vote to see the results
BIOCON is part of below Screeners ↓
Top Mid Cap Stocks with Best Fundamentals
Top Undervalued Mid Cap Stocks
Best Quarterly Growth Mid Cap Stocks
Best 1M Momentum Mid Cap Stocks
Industry Peers & Returns1W1M1Y
BIOCON 13.3% 21.8% 29.3%
SUN PHARMACEUTICAL INDUSTRIES -2.3% -6.5% 55.3%
CIPLA 4.1% -4.8% 55.6%
DR REDDYS LABORATORIES 4% 0.8% 29.4%
ZYDUS LIFESCIENCES -1.2% -5.2% 83.9%
DIVIS LABORATORIES 7.8% 17.4% 20.3%
MANKIND PHARMA 1.3% 7% NA
TORRENT PHARMACEUTICALS 3.9% 5.1% 66.1%
LUPIN 0.6% 0.5% 127.2%

FUNDAMENTAL ANALYSIS OF BIOCON

 
Fundamentals Score
[ Q(TTM): Dec2023, Y: Mar2023
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]

Insights 💡 BIOCON is one of the top 35% companies with good fundamentals ! Discover More →

VALUATION OF BIOCON

 
Valuation Score
[As on : Apr 26,2024 ]

Ratio Consolidated
P/E
P/B
P/S
22.88
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 1,611.00 Cr
[Latest Qtr - Dec2023 - Consolidated Results ]

2.1
P/B Calculated based on Book Value of Rs 17,592.90 Cr
[Latest Year - Mar2023 - Consolidated Results ]

2.52
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 14,612.50 Cr
[Latest Qtr - Dec2023 - Consolidated Results ]

Financial Ratios →

Insights 💡 BIOCON is one of the potential top 12% undervalued companies ! Discover More →

FAIR VALUE OF BIOCON

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
71%
-60%
-66%

Insights 💡 You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF BIOCON


Insights 💡 BIOCON is one of the top 69% companies with bullish price momentum currently! Discover More →

BIOCON vs SENSEX


Insights 💡 You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF BIOCON

Year Debt/Equity ratio
Standalone Consolidated
2023
2022
2021
Avg_3yrs
0.12
0.01
0
0.04
1.01
0.6
0.58
0.73
[Last Annual Data : Mar2023]
Financial Ratios →

PLEDGED PROMOTER SHARES OF BIOCON

Pledged Promoter Shares
0 %
As on : Dec2023

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF BIOCON

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
14.19%
24.97%
248.97%
294.82%
34.43%
43.85%
2665.12%
2127.51%
QtrlyTrend
8
Latest Qtr: Dec2023
Quarterly Result Analysis →


BIOCON related INDICES

BSE Indices1W1M1Y
S&P BSE MIDSMALLCAP 4% 9.7% 67.3%
S&P BSE MID CAP 4% 7.6% 67.4%
S&P BSE 400 MIDSMALLCAP 3.8% 9.1% 62%
S&P BSE 150 MIDCAP 3.6% 7.7% 59.6%
S&P BSE HEALTHCARE 3% 4% 55.2%
NSE Indices1W1M1Y
NIFTY FREE MIDCAP 100 4% 7.6% 62.8%
NIFTY MID SMALL400 3.9% 9.6% 64.8%
NIFTY MIDCAP150 3.7% 8% 60.4%
NIFTY HEALTHCARE 3.2% 2.5% 51.3%
NIFTY PHARMA 3.2% 2.2% 51.4%

You may also like the below Video Courses


FAQ about BIOCON


Is BIOCON good for long term investment?

As on Apr 26,2024, the Fundamentals of BIOCON look Strong and hence it may be good for long term investment! See Financial Performance of BIOCON . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is BIOCON UnderValued or OverValued?

As on Apr 26,2024, BIOCON is Under Valued based on the estimates of intrinsic value and hence may be a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of BIOCON ?

As on Apr 26,2024, the Intrinsic Value of BIOCON is Rs. 768.41 estimated based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 179.21
Fair Value [Median EV / Sales Model] : Rs. 768.41
Fair Value [Median Price / Sales Model] : Rs. 890.23
Estimated Median Fair Value of BIOCON : Rs. 768.41

The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.

Is BIOCON trading at a Premium or Discount?

As on Apr 26,2024, BIOCON is trading at a Discount of -60% based on the estimates of Median Intrinsic Value!